Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Nov 12, 2023 12:08pm
77 Views
Post# 35730879

RE:RE:RE:RE:RE:Options

RE:RE:RE:RE:RE:OptionsGuys don't get me wrong I would love to see $.75+.
The question here if we are discussing them taking the company private is who is  taking the company private ? Is it the group of 10 that owns 62.7% ? Is it Andrew and Jamie who own 42.2% ?

If it is the group of 10 my crude math gives me an average share price of approx. $.35.  If it is Andrew and Jamie I estimate an average share price of not more than $.20.
Will the group of 10 offer more than $.35 ?  If it is Andrew and Jamie they would have to at least offer a break even price for the other 8 investors of $.35.  
 
If the company is sold to outside interests the asking price would obviously be above $.35 but would they get it ?  What is this company worth at this point ?  It will be based not on the average price of the key shareholders but calculated on future revenue potential and we have no idea what that is.
<< Previous
Bullboard Posts
Next >>